The cardiorespiratory response to submaximal exercise in subjects with asthma following pretreatment with controlled release oral salbutamol and high-dose inhaled salmeterol

Respiratory Medicine

Volumn 92, Issue 8, 1998, Pages 1053-1058

  Revill, S M ^a   Morgan, M D L ^a  

^a GLENFIELD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; SALBUTAMOL; SALMETEROL XINAFOATE;

ADULT; ARTICLE; BRONCHODILATATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; EXERCISE INDUCED ASTHMA; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HEART PALPITATION; HEART RATE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG GAS EXCHANGE; MALE; ORAL DRUG ADMINISTRATION; OXYGEN CONSUMPTION; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; TIME; TREMOR;

EID: 0031671195     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(98)90354-7     Document Type: Article

References (13)

1. Information for athletes, coaches and medical practitioners on the permissible use of drugs in amateur sport. International Olympic Committee Medical Commission (1994) (and 1997 update).
2. Revill SM, Macdonald IA, Morgan MDL. Duration of protection from exercise-induced asthma following pre-treatment with high dose salmeterol and controlled release oral salbutamol. Am J Respir Crit Care Med 1997; 155: A964.
3. Guidelines for the measurement of respiratory function. Recommendations of The BTS and ARTP. Respir Med 1994; 88: 165-194.
4. Quanjer PhH. Standardized lung function testing: lung volumes and forced ventilatory flows. 1993 update. Eur Respir J 1993; 6 (Suppl. 16): 4-40.
5. Birmingham AT, Williams EJ, Wilson CG, Wright P. Finger tremor in normal subjects. J Physiol 1978; 276: 20-21.
6. Fitch KD. The use of anti-asthmatic drugs. Sports Med 1986; 3: 136-150.
7. Leitch AG, Clancy LJ, Costello JF, Flenley DC. Effect of intravenous infusion of salbutamol on ventilatory response to carbon dioxide and hypoxia and on heart rate and plasma potassium in normal men. Br Med J 1976; 1: 365-367.
8. Wasserman K, Whipp BJ, Castagna J. Cardiodynamic hyperpnea: hyperpnea secondary to cardiac output increase. J Appl Physiol 1974; 86: 457-464.
9. Robertson W, Simkins J, O'Hickey SP, Freeman S, Cayton RM. does single dose salmeterol affect exercise capacity in asthmatic men? Eur Respir J 1994; 7: 1978-1984.
10. McDowell SL, Fleck SJ, Storms WW. The effects of salmeterol on power output in nonasthmatic athletes. J Allergy Clin Immunol 1997; 99: 443-449.
11. Morton AR, Joyce KJ, Papalia SM, Carroll NG, Fitch KD. Is salmeterol ergogenic? Clin J Sport Med 1996; 6: 220-225.
12. Sue-Chu M, Helgerud A, Reinertsen R, Bjermer L. No ergogenic effects of inhaled salmeterol (50 μg) and salbutamol (1-2 mg). Am J Respir Crit Care Med 1997; 155: A344.
13. Martineau L, Horan MA, Rothwell NJ, Little RA. Salbutamol, a beta adrenergic agonist, increases skeletal muscle strength in young men. Clin Sci 1992; 83: 615-621.